UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Vitamin D status in pediatric irritable bowel syndrome

PloS one, 2017-02, Vol.12 (2), p.e0172183-e0172183

2017

Volltextzugriff (PDF)

P042 Early Versus Later Use of Vedolizumab In IBD: Patient Characteristics And Treatment Patterns In The Real World (RALEE)

The American journal of gastroenterology, 2021-12, Vol.116 (Suppl 1), p.S11-S11

2021

Volltextzugriff (PDF)

S768 Costs for Treating Patients With Ulcerative Colitis With Vedolizumab or Adalimumab Based on Endoscopic Improvement Data From the VARSITY Trial

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S355-S355

2021

Volltextzugriff (PDF)

S984 Comparison of Surgery Rates in Biologic-Naive Patients With Crohn’s Disease Who Were Treated With Vedolizumab or Ustekinumab: Findings From SOJOURN

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e715-e716

2022

Volltextzugriff (PDF)

S800 Dose Escalation of Biologic Therapies in Biologic Treatment-Naïve Patients With Crohn’s Disease: Results From the ODESSA-CD Study

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e570-e571

2022

Volltextzugriff (PDF)

Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN

BMC gastroenterology, 2023-03, Vol.23 (1), p.87-87, Article 87

2023

Volltextzugriff (PDF)

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY

BMC gastroenterology, 2024-09, Vol.24 (1), p.314-12, Article 314

2024

Volltextzugriff (PDF)

S921 Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings from ROTARY-1

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S435-S436

2021

Volltextzugriff (PDF)

Correction: Vitamin D status in pediatric irritable bowel syndrome

PloS one, 2017-03, Vol.12 (3), p.e0173779-e0173779

2017

Volltextzugriff (PDF)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

BMC gastroenterology, 2022-12, Vol.22 (1), p.501-501, Article 501

2022

Volltextzugriff (PDF)

Lactose intolerance: lack of evidence for short stature or vitamin D deficiency in prepubertal children

PloS one, 2013-10, Vol.8 (10), p.e78653-e78653

2013

Volltextzugriff (PDF)

Sa1548: UPTAKE AND PATTERNS OF INFLUENZA VACCINE ADMINISTRATION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CLAIMSBASED ANALYSIS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-409-S-409

2022

Volltextzugriff (PDF)

IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S11-S12

2022

Volltextzugriff (PDF)

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S8-S9

2022

Volltextzugriff (PDF)

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S7-S8

2022

Volltextzugriff (PDF)

DOSE ESCALATION OF BIOLOGIC THERAPIES IN BIOLOGIC TREATMENT-NAÏVE ADULT PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE ODESSA DATABASE STUDY

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S9-S10

2022

Volltextzugriff (PDF)

EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S105-S106

2022

Volltextzugriff (PDF)

Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY

Inflammatory bowel diseases, 2024-10, Vol.30 (10), p.1776-1787

2024

Volltextzugriff (PDF)

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

Inflammatory bowel diseases, 2022-01, Vol.28 (Supplement_1), p.S8-S9

2022

Volltextzugriff (PDF)

IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS

Inflammatory bowel diseases, 2022-01, Vol.28 (Supplement_1), p.S11-S12

2022

Volltextzugriff (PDF)

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

Inflammatory bowel diseases, 2022-01, Vol.28 (Supplement_1), p.S7-S8

2022

Volltextzugriff (PDF)

EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)

Inflammatory bowel diseases, 2022-01, Vol.28 (Supplement_1), p.S105-S106

2022

Volltextzugriff (PDF)

DOSE ESCALATION OF BIOLOGIC THERAPIES IN BIOLOGIC TREATMENT-NAÏVE ADULT PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE ODESSA DATABASE STUDY

Inflammatory bowel diseases, 2022-01, Vol.28 (Supplement_1), p.S9-S10

2022

Volltextzugriff (PDF)

Mo1552: ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-815-S-816

2022

Volltextzugriff (PDF)

Mo1550: PERSISTENCE OF FIRST AND SECOND LINES OF BIOLOGIC TREATMENT ACROSS DIFFERENT TREATMENT SEQUENCES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING AT LEAST TWO BIOLOGICS: FINDINGS FROM ROTARY PART A

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-814-S-815

2022

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(57)
Buchkapitel
(1)

Sprache

Englisch
(58)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Vitamin D status in pediatric irritable bowel syndrome

P042 Early Versus Later Use of Vedolizumab In IBD: Patient Characteristics And Treatment Patterns In The Real World (RALEE)

S768 Costs for Treating Patients With Ulcerative Colitis With Vedolizumab or Adalimumab Based on Endoscopic Improvement Data From the VARSITY Trial

S984 Comparison of Surgery Rates in Biologic-Naive Patients With Crohn’s Disease Who Were Treated With Vedolizumab or Ustekinumab: Findings From SOJOURN

S800 Dose Escalation of Biologic Therapies in Biologic Treatment-Naïve Patients With Crohn’s Disease: Results From the ODESSA-CD Study

Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY

S921 Persistence of First and Second Lines of Biologic Treatment Across Different Treatment Sequences in Patients With Inflammatory Bowel Disease Receiving at Least Two Biologics: Findings from ROTARY-1

Correction: Vitamin D status in pediatric irritable bowel syndrome

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

Lactose intolerance: lack of evidence for short stature or vitamin D deficiency in prepubertal children

Sa1548: UPTAKE AND PATTERNS OF INFLUENZA VACCINE ADMINISTRATION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CLAIMSBASED ANALYSIS

IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

DOSE ESCALATION OF BIOLOGIC THERAPIES IN BIOLOGIC TREATMENT-NAÏVE ADULT PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE ODESSA DATABASE STUDY

EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)

Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS

ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

EARLY VERSUS DELAYED INITIATION OF VEDOLIZUMAB IN ULCERATIVE COLITIS: TREATMENT RESPONSE IN THE REAL WORLD (RALEE)

DOSE ESCALATION OF BIOLOGIC THERAPIES IN BIOLOGIC TREATMENT-NAÏVE ADULT PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE ODESSA DATABASE STUDY

Mo1552: ADVERSE CLINICAL OUTCOMES IN PATIENTS WITH CROHN’S DISEASE RECEIVING DIFFERENT SEQUENCES OF FIRST- AND SECOND-LINE BIOLOGIC TREATMENTS: FINDINGS FROM ROTARY

Mo1550: PERSISTENCE OF FIRST AND SECOND LINES OF BIOLOGIC TREATMENT ACROSS DIFFERENT TREATMENT SEQUENCES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING AT LEAST TWO BIOLOGICS: FINDINGS FROM ROTARY PART A

Suchergebnisse filtern